GHK-Cu for Skin After GLP-1 Weight Loss

Ozempic Face Is Not a Drug Effect

Somebody asks a version of this question in a weight loss forum every week. They have lost thirty or fifty pounds, their face looks a decade older in photographs, and they want to know whether a copper peptide will undo it. The most upvoted replies are almost always the deflating ones, and the deflating ones are correct. That is worth saying up front, because the rest of this only makes sense once the premise is fixed.

Semaglutide, the molecule in Ozempic and Wegovy, and tirzepatide, the molecule in Mounjaro and Zepbound, are not doing anything unusual to your skin. They are producing fast, substantial weight loss. Your face is not exempt from that. It carries a meaningful amount of subcutaneous fat in the cheeks, the temples, and the periorbital region, and that fat is a large part of what a rested, younger-looking face is made of. Take it away quickly and the underlying structure shows through. The skin did not fail. The thing it was draped over got smaller.

The same phenomenon has been described for as long as people have lost weight quickly. Bariatric surgery patients see it. Physique competitors see it at the end of a cut. People recovering from a long illness see it. What changed is the size of the population experiencing it at once, which is why a nickname attached to one brand ended up standing in for a general effect of rapid fat loss.

Daneshgaran G, Shauly O, Gould DJ. "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. Aesthetic Surgery Journal Open Forum, 2025; 7: ojaf056. The review describes the term as shorthand for exaggerated volume loss producing the appearance of advanced facial aging, and tracks public searches for the phrase rising alongside searches for facial filler. View study

Barone M, Brunetti B, D’Emilio R, Caputo MG, Tenna S, Persichetti P. Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review. Aesthetic Plastic Surgery, 2026; 50(13): 5403-5407. Forty studies reviewed. The dermatologic changes are attributed to rapid reduction of subcutaneous adipose tissue, with risk concentrated in older patients, faster loss, poor hydration, and low protein intake. View study

If you want the longer general explainer on the mechanism and the timeline, that lives in our Ozempic face and loose skin guide Read nextOzempic Face, Loose Skin, and What Actually HelpsRapid weight loss on GLP-1s can change how your face and skin look. What is actually happening underneath, why skin recovery lags fat loss, and which peptides support the repair process.Read article . This page is narrower. It is about whether GHK-Cu specifically, and the KLOW blend that contains it, are the right tool for what you are actually looking at.

Three Problems, One Name

Ozempic face gets used for three separate problems that have three separate solutions. Sorting yours into the right bucket is the highest-value thing you can do before spending anything.

Deflation: the volume is gone

Hollow temples, flattened cheeks, a shadow under the eye that was not there before, folds that read deeper because the tissue above them no longer sits forward. The skin itself may be perfectly healthy. There is simply less underneath it. A 2026 anatomical review in Dermatologic Surgery describes the change as involving several layers at once: deflation of the superficial fat compartments, loss of deep support, skeletal remodeling with age, and increased laxity on top of all of it.

Frank K, Guertler A, Hoffmeister V, Kohler L, Nikolis A, Prantl L, Pupo D, Moellhoff N, Hopf M, Heiland M, Alfertshofer M. GLP-1-Induced Weight Loss and the Face: Anatomical Mechanisms and Rationale for Collagen-Stimulating and Volumizing Aesthetic Treatments. Dermatologic Surgery, 2026; 52(6S): S55-S60. View study

Skin quality: the dermis changed

Thinner-feeling skin, a crepey texture on the cheeks or the backs of the hands, less bounce, a duller surface. This is the dermal layer, and it is the one that responds to collagen and elastin signaling. It is also the only one of the three where a peptide has a plausible mechanism to contribute.

Laxity: the envelope is too big

Skin that hangs. Under the jaw, on the upper arms, across the lower abdomen, on the inner thighs. This is a mechanical mismatch between the surface area of your skin and the volume it now has to cover. It is not a signaling problem, and it does not resolve because you improved collagen synthesis by some percentage. Past a certain degree, the surface area has to be removed.

What GHK-Cu Actually Does

GHK-Cu is a copper-binding tripeptide, three amino acids with a copper ion attached. It occurs naturally in human plasma and declines substantially with age. It is not a novelty compound. The core biology has been examined since the 1970s, and the reason it keeps coming up in skin conversations is that the collagen finding is old, specific, and reproducible.

The foundational demonstration is Maquart and colleagues in 1988, showing that the tripeptide-copper complex stimulated collagen synthesis in cultured fibroblasts. Fibroblasts are the cells that build the dermal matrix, so this is upstream of everything people want from a skin product. Later work extended the picture: GHK participates in tissue remodeling as a matrikine, a signal released from the matrix when tissue is damaged, and gene expression analysis has associated it with a broad shift toward repair-oriented and antioxidant programs.

Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters, 1988; 238(2): 343-346. View study

Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 2008; 19(8): 969-988. View study

Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018; 19(7): 1987. View study

Two honest qualifications belong right next to that. First, most of the controlled human skin data on GHK-Cu is topical, not injected. Randomized trials of subcutaneous GHK-Cu in humans do not exist, so the case for injection rests on mechanism, systemic delivery, and clinical experience rather than on injectable-specific trials. Second, Loren Pickart discovered the molecule and also founded a company selling copper peptide skincare, which does not invalidate the independent work but is worth knowing when you read the review literature. The full breakdown, including the gene expression data and the topical versus injectable question, is in the GHK-Cu guide Read nextGHK-Cu Copper Peptide 2026: Skin, Hair & Tissue RepairHow GHK-Cu rebuilds collagen, influences thousands of genes, and helps skin and hair, plus the research, dosage, side effects, and how the injectable differs from topical copper-peptide skincare.Read article .

One more distinction that trips people up. Topical copper peptide serums are sold over the counter as cosmetics and are widely available. Injectable GHK-Cu is a compounded prescription medication and is not FDA-approved for any indication. Those are different products with different regulatory status, different delivery, and different expectations, and comparing a $25 serum to a prescription vial as though they are interchangeable is how most of the confusion starts.

What GHK-Cu Cannot Do

This is the section that will save you money, so it gets the same weight as the section above it.

It does not restore lost facial fat

Nothing in a vial rebuilds a deflated fat compartment. Fat volume is replaced with volume: autologous fat grafting, hyaluronic acid filler, biostimulatory injectables placed by a clinician who does that work, or in some cases simply arriving at a weight your face can carry. The Dermatologic Surgery review cited above lays out exactly this logic, treating collagen stimulation and structural volume replacement as two different jobs done with two different tools. A peptide is not on the volume side of that list.

It does not tighten significantly loose skin

A modest improvement in dermal quality is not the same thing as removing surface area. Once a skin envelope is genuinely redundant, the honest options are energy-based devices for mild cases and surgical excision for the rest. Post-bariatric research has looked at exactly this population, and the people with clinically meaningful excess skin are the people who end up evaluating body contouring, not the people who fixed it with a topical or an injectable.

Monpellier VM, Antoniou EE, Mulkens S, Janssen IMC, van der Molen ABM, Jansen ATM. Body Contouring Surgery after Massive Weight Loss: Excess Skin, Body Satisfaction, and Qualification for Reimbursement in a Dutch Post-Bariatric Surgery Population. Plastic and Reconstructive Surgery, 2019; 143(5): 1353-1360. View study

It does not change bone or deep structure

Part of what reads as facial aging after a large weight loss in an older adult is skeletal, and skeletal change is entirely out of scope for any injectable peptide. If the shape of the orbital rim or the projection of the midface is a component of what you are seeing, no amount of collagen support touches it.

Where KLOW Fits, and Where It Does Not

KLOW gets named unprompted in these conversations often enough that it deserves a direct answer. It is a four-peptide blend in a single vial: BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide , GHK-Cu, KPV, and TB-500, dosed at 3mg, 10mg, 3mg, and 3mg per mL in a 5mL vial, given subcutaneously, at $349 for a one month supply.

The important number there is the GHK-Cu concentration. It is 10mg/mL, which is the same concentration as the standalone GHK-Cu vial. Choosing KLOW is therefore not a way to get a stronger dose of the skin peptide. It is a way to add three other things to it: BPC-157 for repair signaling and angiogenesis, TB-500 for cell migration and systemic recovery, and KPV, a fragment of alpha-MSH, for inflammatory signaling.

So the decision is not really about skin. If skin quality is the only thing you care about, standalone GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide at $229 a month delivers the same GHK-Cu. KLOW makes sense when there is a second agenda in the room: a shoulder that has been annoying you for a year, a gut that has not been right since you started losing weight, joint discomfort that showed up alongside the loss. In that situation you are paying $120 more for three additional peptides rather than for a better skin outcome.

Matching the Problem to the Fix

What a Realistic Result Looks Like

If you have sorted your problem into the skin quality bucket and decided GHK-Cu is worth trying, here is the honest shape of what that looks like. Nothing here is a promise, and individual results vary widely.

PeRx ships GHK-Cu fully reconstituted and ready to use. There is nothing to mix. It is a subcutaneous injection on a schedule set by the prescribing provider, and the solution carries a faint blue tint from the copper complex.

The Boring Parts That Matter More

The Barone review identified five risk factors for worse skin outcomes during GLP-1 weight loss: advanced age, a long history of obesity, rapid loss, poor hydration, and insufficient protein. Two of those you cannot change. Three of them you can, and they are almost certainly worth more than anything you inject.

Pace of loss. Fat can be mobilized in hours. Collagen turns over on a timescale of a year or more. Every point of separation between those two rates is visible on your face and your abdomen. Slowing down is unglamorous and it is the single most effective lever available.

Protein. Collagen is a protein and elastin is a protein, and fibroblasts cannot build either out of nothing. Appetite suppression makes underconsumption easy to miss, which is the same reason protein matters for holding onto muscle. We cover that side of it in the muscle loss on GLP-1s guide Read nextHow to Keep Muscle While Taking Ozempic, Wegovy, or MounjaroUp to 40% of weight lost on GLP-1 medications is lean muscle. Here is what the research actually shows, why it happens, and which growth hormone peptides providers prescribe to preserve lean mass during a caloric deficit.Read article and the muscle preservation stack Read nextPeptides to Preserve Muscle on GLP-1: The Stack ProtocolA protocol-depth read on Tesamorelin, CJC-1295/Ipamorelin, BPC-157, MOTS-c, and NAD+ for adults who lost (or are losing) lean mass on Ozempic, Wegovy, Mounjaro, or Zepbound.Read article .

Hydration. Fluid intake is partly appetite-driven, so it tends to fall alongside food intake without anyone deciding to drink less. Dehydrated skin reads worse in every dimension people complain about, and it is the cheapest thing on this list to fix.

Sun protection and retinoids. These remain the best-evidenced interventions in all of skin aging. A peptide is an addition to that foundation, not a replacement for it, and if the foundation is missing then the peptide is being asked to do a job it was never going to do.

Skin is also rarely the only thing changing during a GLP-1 course. Muscle, energy, gut tolerance, and hair all come up in the same conversations, and each has a different answer. The overview of which peptides pair with a GLP-1 Read nextPeptides to Take With a GLP-1: The EvidenceSearch this question and you get a stack. Every result recommends four or five peptides, none of them ranks the options, and none of them tells you which ones have human data behind them. This page sorts the same list into three tiers and says out loud which tier each one lands in.Read article sets out what belongs in which category, which is useful if you are trying to decide where a limited budget actually goes.

Common Questions